Rivaroxaban (BAY 59-7939, Xarelto) in ODT form + Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clinical Pharmacology
Conditions
Clinical Pharmacology
Trial Timeline
Jan 21, 2019 → Apr 12, 2019
NCT ID
NCT04511637About Rivaroxaban (BAY 59-7939, Xarelto) in ODT form + Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Rivaroxaban (BAY 59-7939, Xarelto) in ODT form + Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form is a phase 1 stage product being developed by Bayer for Clinical Pharmacology. The current trial status is completed. This product is registered under clinical trial identifier NCT04511637. Target conditions include Clinical Pharmacology.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04511611 | Phase 1 | Completed |
| NCT04511637 | Phase 1 | Completed |
Competing Products
20 competing products in Clinical Pharmacology